Johnson & Johnson Family of Companies
1 Johnson & Johnson Plaza
New Brunswick
New Jersey
08933
United States
Tel: 732-524-0400
Fax: 732-524-3300
Website: http://www.jnj.com/
2132 articles with Johnson & Johnson Family of Companies
-
In a filing with the U.S. Securities and Exchange Commission, Johnson & Johnson said it will abandon development of AL-8176, one of the assets it acquired in the Alios deal.
-
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results - March 19, 2019
3/19/2019
Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, April 16th, to review first-quarter results.
-
March is National Women’s Month with March 8 specifically designated as International Women’s Day. Although this is not remotely a comprehensive list, BioSpace recognizes these 10 women (in no particular order) as being especially influential in the biopharma industry.
-
With a major lawsuit in Oklahoma targeting Johnson & Johnson and Purdue Pharma’s involvement in the opioid epidemic starting in May, many of the legal documents are being released, with strategies and sometimes incendiary rhetoric coming to light.
-
Humira generated nearly $20 billion in revenue for the Illinois-based company. Celgene's Revlimid earned about half-as-much in 2018.
-
Janssen Submits Application to U.S. FDA Seeking Approval of DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
3/12/2019
Application supported by the Phase 3 MAIA study being reviewed under the FDA Real-Time Oncology Review pilot program
-
Often, patients prefer oral medications over receiving an injection or infusion, but daily pills sometimes result in compliance problems. In the case of this combination injection, it would, if approved, require patients to visit a clinic or physician once a month for the shot.
-
Janssen Announces Results Of Two Phase 3 Studies Which Showed Long-Acting Injectable HIV Treatment Regimen Of Rilpivirine And Cabotegravir Demonstrated Comparable Safety And Efficacy To Daily Oral HIV Therapy
3/7/2019
ATLAS and FLAIR studies presented at the 2019 Conference on Retroviruses and Opportunistic Infections met primary endpoints showing long-acting, injectable regimen to be effective in virally suppressed adults living with HIV
-
Houston based depression psychiatrist, Dr. Sandhya Prashad, M.D., tells how this new drug might save lives and cost less than expected
3/6/2019
FDA approves Spravato, a version of ketamine backed by Johnson & Johnson that sees rapid results in patients battling treatment resistant depression and suicide
-
New Global Headquarters for Johnson & Johnson Human Performance Institute® Reimagines Workplace Wellbeing
3/5/2019
Multi-sensory Experience Fuels Physical, Mental, Emotional and Spiritual Energy for Higher Performance and Purposeful Living
-
Johnson & Johnson to Participate in Barclays Global Healthcare Conference - February 28, 2019
2/28/2019
Johnson & Johnson will participate in the Barclays Global Healthcare Conference on Thursday, Mar. 14, at the Loews Miami Beach Hotel, Miami, FL. Tom Cavanaugh, President, Oncology and Catherine Owen, President, Immunology will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time).
-
U.S. Senator Chuck Grassley (R-Iowa) set the tone early, mentioning his constituents rationing drugs because of high prices or “leaving their prescription on the pharmacy counter because it costs too much,” but acknowledging that innovations “take time and money.”
-
Waltham, Mass.-based Morphic Therapeutic and Janssen Biotech, a division of Johnson & Johnson, entered into a collaborative deal to develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies.
-
Seven pharma executives will enter the Congressional crucible next week as they face questions and concerns over the rising costs of prescription drugs.
-
Johnson & Johnson’s iconic talcum powder product has been the subject of lawsuits and a scathing report that indicated the company allegedly knew that carcinogenic asbestos was sometimes found in the product. As a result, the company has received subpoenas from the federal government.
-
It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list.
-
As the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) rolls on, companies are showcasing more data in presentations. BioSpace takes a look at some of the latest.
-
Johnson & Johnson to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
2/14/2019
Johnson & Johnson will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, Feb. 28th, at Lotte New York Palace, NY.
-
Johnson & Johnson Announces Agreement to Acquire Auris Health, Inc.
2/13/2019
Auris Health's Robotic Platform Expands Johnson & Johnson's Digital Surgery Portfolio
-
Johnson & Johnson plunked down $3.4 billion in cash to acquire privately held Auris Health, Inc., a company that developed robotic endoscopic technologies that can be used in the treatment of lung cancer.